Valuation : Patrys Limited

Market Cap 23.33M 16.82M 14.47M 13.62M 12.44M 23.27M 1.59B 161M 62.43M 815M 63.15M 61.78M 2.62B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 16.28M 14.01M 13.18M 12.04M 22.53M 1.54B 156M 60.45M 789M 61.14M 59.81M 2.54B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 month-9.09%
3 months-30.23%
6 months-21.05%
Current year+7.14%
1 week 0.03
Extreme 0.03
0.03
1 month 0.03
Extreme 0.03
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/23 Expiration

Chief Executive Officer

396,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+100.01%-75.00% 14.39M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-1.52%+46.40%+86.87% 66.32B
-0.31%+6.54%-11.39%+378.92% 27.66B
+0.86%+1.65%+0.25%-14.95% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%-0.09%+24.64%-18.36% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.20%+8.37%+57.87%+164.98% 14.65B
Average -1.20%-0.59%+49.94%+154.05% 28.32B
Weighted average by Cap. -1.50%-0.45%+40.23%+138.87%

Financials

2024 2025
Net sales 1.39M 1M 865K 814K 743K 1.39M 94.88M 9.61M 3.73M 48.68M 3.77M 3.69M 157M 829K 597K 514K 484K 442K 826K 56.39M 5.71M 2.22M 28.93M 2.24M 2.19M 93.2M
Net income -3.54M -2.55M -2.2M -2.07M -1.89M -3.53M -241M -24.41M -9.47M -124M -9.58M -9.37M -398M -3.01M -2.17M -1.87M -1.76M -1.61M -3.01M -205M -20.78M -8.06M -105M -8.16M -7.98M -339M
Net Debt -2.24M -1.62M -1.39M -1.31M -1.19M -2.23M -152M -15.45M -6M -78.24M -6.06M -5.93M -252M -742K -535K -461K -433K -396K -740K -50.53M -5.12M -1.99M -25.92M -2.01M -1.97M -83.52M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
04/09/26 A$0.0300 0.00% 620,799
03/09/26 A$0.0300 0.00% 969,792
02/09/26 A$0.0300 -3.23% 582,118
01/09/26 A$0.0310 +3.33% 17,733
31/08/26 A$0.0300 -3.23% 102,429